Cardiovascular risk in aging and obesity: Is there a role for GH?

被引:44
作者
Gola, M [1 ]
Bonadonna, S [1 ]
Doga, M [1 ]
Mazziotti, G [1 ]
Giustina, A [1 ]
机构
[1] Univ Brescia, Dept Internal Med, Endocrine Sect, I-25125 Brescia, Italy
关键词
cardiovascular risk; GH; aging; obesity; body composition; insulin; lipids;
D O I
10.1007/BF03347561
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
GH has significant impact in adults. In fact, patients with the GH deficiency (GHD) syndrome are now recognized as having an increased cardiovascular risk. The effects of human aging on GH secretion have been evaluated by a number of researchers. Studies of 24 h secretion of GH have shown variable reductions in most 24-h GH secretory parameters in middle-aged and in older men and women, resulting in a decrease in plasma levels of its anabolic mediator IGF-I. Obesity is also associated with several endocrine and metabolic abnormalities. These include decreased serum GH concentrations, reduced GH half-life, frequency of GH secretory episodes and daily GH production rate. The mechanism of the low GH in obesity is not completely understood nor is it clear whether its relationship with visceral adiposity is causal. The aim of this article will be to review the available clinical data concerning the potential involvement of "subclinical" or perhaps better "functional" GHD, which is observed in aging and obesity, in the increase in cardiovascular risk which characterizes these two conditions.
引用
收藏
页码:759 / 767
页数:9
相关论文
共 73 条
[11]   EFFECT OF COMBINED ADMINISTRATION OF GROWTH-HORMONE (GH)-RELEASING HORMONE, GH-RELEASING PEPTIDE-6, AND PYRIDOSTIGMINE IN NORMAL AND OBESE SUBJECTS [J].
CORDIDO, F ;
PENALVA, A ;
PEINO, R ;
CASANUEVA, FF ;
DIEGUEZ, C .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1995, 44 (06) :745-748
[12]   CHOLINERGIC RECEPTOR ACTIVATION BY PYRIDOSTIGMINE RESTORES GROWTH-HORMONE (GH) RESPONSIVENESS TO GH-RELEASING HORMONE ADMINISTRATION IN OBESE SUBJECTS - EVIDENCE FOR HYPOTHALAMIC SOMATOSTATINERGIC PARTICIPATION IN THE BLUNTED GH RELEASE OF OBESITY [J].
CORDIDO, F ;
CASANUEVA, FF ;
DIEGUEZ, C .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1989, 68 (02) :290-293
[13]   Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression [J].
Cordido, F ;
Peino, R ;
Penalva, A ;
Alvarez, CV ;
Casanueva, FF ;
Dieguez, C .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (03) :914-918
[14]   HUMAN GROWTH-HORMONE AND HUMAN AGING [J].
CORPAS, E ;
HARMAN, SM ;
BLACKMAN, MR .
ENDOCRINE REVIEWS, 1993, 14 (01) :20-39
[15]   CLINICAL ASPECTS OF GROWTH-HORMONE DEFICIENCY IN ADULTS [J].
DEBOER, H ;
BLOK, GJ ;
VANDERVEEN, EA .
ENDOCRINE REVIEWS, 1995, 16 (01) :63-86
[16]   INSULIN RESISTANCE - A MULTIFACETED SYNDROME RESPONSIBLE FOR NIDDM, OBESITY, HYPERTENSION, DYSLIPIDEMIA, AND ATHEROSCLEROTIC CARDIOVASCULAR-DISEASE [J].
DEFRONZO, RA ;
FERRANNINI, E .
DIABETES CARE, 1991, 14 (03) :173-194
[17]   THE TRIUMVIRATE - BETA-CELL, MUSCLE, LIVER - A COLLUSION RESPONSIBLE FOR NIDDM [J].
DEFRONZO, RA .
DIABETES, 1988, 37 (06) :667-687
[18]   Continuous 24-hour intravenous infusion of recombinant human growth hormone (GH)-releasing hormone-(1-44)-amide augments pulsatile, entropic, and daily rhythmic GH secretion in postmenopausal women equally in the estrogen-withdrawn and estrogen-supplemented states [J].
Evans, WS ;
Anderson, SM ;
Hull, LT ;
Azimi, PP ;
Bowers, CY ;
Veldhuis, JD .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (02) :700-712
[19]   A preliminary study of growth hormone in the treatment of dilated cardiomyopathy [J].
Fazio, S ;
Sabatini, D ;
Capaldo, B ;
Vigorito, C ;
Giordano, A ;
Guida, R ;
Pardo, F ;
Biondi, B ;
Sacca, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (13) :809-814
[20]  
FINK RI, 1983, J CLIN INVEST, V71, P1523, DOI 10.1172/JCI110908